Oxford BioMedica's posts positive cancer drug results
8th Oct 2005, 05:13 GMT
Preliminary results from a phase II trial of Oxford BioMedica's TroVax have shown the product to be safe and effective in patients with renal cell carcinoma.
Oxford BioMedica's posts positive cancer drug results related news:
- Oxford Biomedica Plc: Oxford Biomedica Plc announces Prelim Phase II Results — Market Wire - Pharmaceuticals and Biotech
- Positive results for PSMA prostate cancer drug — Pharmaceutical Business Review Online
- Oxford Biomedica Plc announces Prelim Phase II Results — ArriveNet : Health
- Endo Posts Positive Painkiller Data — Operations-Related News from StratCenter.com
- Cervical Cancer Drug Hopes — Rednova News - Health
- Miracle Of New Cervical Cancer Jab — Sky News UK: Brings you closer to the news across Britain
- Positive late stage test for Endo painkiller — Pharmaceutical Business Review Online
- FDA Approves New Use for Breast Cancer Drug — WebMD Health Headlines
- Cervical Cancer Vaccine Could Be on Shelves in a Year — Rednova News - Health
- Vaccine Raises Hopes Over Cervical Cancer — Sky News Home: First for breaking news around the UK and the globe
Latest news from Pharmaceutical Business Review Online:
- Celesio revenues, profits up
- Amgen arthritis drug shows sustained safety and efficacy
- Study supports cardiovascular safety of naproxen
- Cangene chickenpox drug granted orphan status
- Reata brain cancer therapy shows strong activity
- Novartis diabetes drug faces three month delay
- Favrille drug fails secondary goal
- Neurogen commences human testing of obesity drug
- Aeterna prostate cancer drug shows promise
- Isis says new drug effective against cholesterol